Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

To date, there is a lack of long-term safety and efficacy data for iron chelation therapy in transfusion-dependent patients with sickle cell disease (SCD). To evaluate the long-term safety and efficacy of deferasirox (a once-daily oral iron chelator), patients with SCD completing a 1-year, Phase II,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Vichinsky, Elliott, Bernaudin, Françoise, Forni, Gian Luca, Gardner, Renee, Hassell, Kathryn, Heeney, Matthew M, Inusa, Baba, Kutlar, Abdullah, Lane, Peter, Mathias, Liesl, Porter, John, Tebbi, Cameron, Wilson, Felicia, Griffel, Louis, Deng, Wei, Giannone, Vanessa, Coates, Thomas
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2011
Matèries:
Red Cells and Iron
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3170481/
https://ncbi.nlm.nih.gov/pubmed/21592110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2011.08720.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars